Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000

Fertility and Sterility

Volumn 75, Issue 5, 2001, Pages 898-915

  Godsland, Ian F ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Estrogens; Lipoprotein (a); Lipoproteins; Postmenopausal hormone replacement therapy; Progestogens; Selective estrogens receptor modulators; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTRONE SULFATE; ETHINYLESTRADIOL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORGESTREL; PIPERAZINE ESTRONE SULFATE; PLACEBO; PROGESTERONE; RALOXIFENE; TIBOLONE; TRIACYLGLYCEROL;

ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ANABOLIC AGENTS; APOLIPOPROTEINS; APOPROTEIN(A); CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; NORPREGNENES; PROGESTINS; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRIGLYCERIDES;

EID: 0035035574     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)01699-5     Document Type: Article

References (269)

1. Cardiovascular mortality and noncontraceptive use of estrogen in women; results from the Lipid Research Clinics Program Follow-up Study
2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
3. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
4. Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women
5. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys
6. Effects of hormone replacement therapy on the endometrium and lipid parameters; a review of randomized clinical trials, 1985 to 1995
7. Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins
8. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives
9. The effect of desogestrel for hormone replacement therapy on the blood lipid profiles of postmenopausal women
10. Clinical evaluation of near-continuous oral micronised progesterone therapy in estrogenized postmenopausal women
11. Responses of HDL subclasses, Lp(AI) and Lp(AI:AII) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women
12. Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women
13. The effect of hormone replacement therapy on metabolism of lipoprotein remnants in postmenopausal women
14. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy
15. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
16. The Postmenopausal/Progestin Intervention Study; primary outcomes in adherent women
17. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
18. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women
19. The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids
20. A two-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin
21. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations
22. Metabolic effect of conjugated oestrogens (USP) on lipids and lipoproteins
23. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
24. Metabolic effect of two hormonal preparations in postmenopausal women
25. The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period
26. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
27. Clearance of triglycerides from the circulation and its relationship to serum lipoproteins; influence of age and sex
28. Sex, plasma lipoproteins, and atherosclerosis; prevailing assumptions and outstanding questions
29. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors; results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)
30. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study
31. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations
32. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) in healthy postmenopausal women
33. Hormonal regulation of lipoprotein(a) levels; effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women
34. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause
35. Effects of conjugated equine oestrogens and oestriol on blood clotting, plasma lipids and endometrial proliferation in post-menopausal women
36. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women
37. Equine estrogen-dydrogesterone therapy in the management of postmenopausal women
38. Biologic effects of transdermal estradiol
39. The effects of conjugated equine estrogens with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women
40. A prospective one-year study of estrogen and progestin in postmenopausal women; effects on clinical symptoms and lipoprotein lipids
41. Serum lipoprotein effects of conjugated esterogen and sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women
42. Effect of progestin therapy on cortical and trabecular bone; comparison with estrogen
43. A short-term comparison of the effects of clomiphene citrate and conjugated equine estrogen in menopausal/castrate women
44. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with Utrogestan in menopausal women
45. Effects of unopposed conjugated equine estrogen on lipoprotein composition and apolipoprotein-E distribution
46. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women
47. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
48. Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women
49. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations
50. The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women
51. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin
52. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women
53. Effect of conjugated estrogens with and without medrogestone; a prospective study
54. Comparison of the impact of oral versus transdermal estrogen on serum lipoproteins
55. The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens; an open randomized comparative study
56. Postmenopausal hormone replacement therapy with low-dose medroxyprogesterone acetate. Endometrium, plasma lipids, lipoproteins and apolipoproteins
57. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy
58. Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen
59. Lipoprotein (a) and other lipids after oophorectomy and estrogen replacement therapy
60. Mechanisms of accumulating cholesterol; effects of estrogen replacement therapy on lipid metabolism in postmenopausal/oophorectomized women
61. A controlled trial of raloxifene (LY139481) HCL; impact on bone turnover and serum lipid profile in healthy postmenopausal women
62. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy
63. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy; a two-year prospective study
64. Effects of hormone-replacement therapy on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause; implications for prevention of atherosclerosis
65. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women
66. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
67. Estrogen replacement therapy and coagulation; relationship to lipid and lipoprotein changes
68. Effects of oral and transdermal hormone replacement therapy on lipoprotein (a) and lipids; a randomized controlled trial
69. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone
70. Estrogen-induced small low-density lipoprotein particles in postmenopausal women
71. Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women
72. Hormone replacement therapy and lipid-lipoprotein concentrations
73. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women; a two-year, placebo-controlled study
74. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia
75. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient
76. Continuous estrogen/progestin therapy in menopause
77. Lipid changes after hormone replacement therapy for menopause
78. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient
79. Postmenopausal hormone replacement with a combination estrogen-progestin regime for five days per week
80. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women; a double-blind, prospective study of sequential versus continuous therapy
81. Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women
82. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women; a randomized trial
83. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
84. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy
85. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behaviour of apolipoproteins AI and B
86. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia
87. The effects of two fixed hormonal replacement therapy protocols on blood lipid profile
88. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein
89. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins
90. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables
91. Phasic serum lipid excursions during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone. acetate
92. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women
93. Increased activity of lecithin; cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women
94. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations
95. Oestrogen-progestin therapy and the lipid balance of post-menopausal women
96. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone
97. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement
98. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women
99. Cyclic hormonal replacement therapy after the menopause; transdermal versus oral treatment
100. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I
101. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women
102. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement
103. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium
104. Low-dose progesterone therapy in oestrogenised postmenopausal women; effects on plasma lipids, lipoproteins and liver function parameters
105. Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women
106. Comparison of two equine oestrogen-dydrogesterone regimens in the climacteric
107. The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women
108. The effects of estradiol valerate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women
109. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women
110. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women
111. A comparison of the effects on lipoproteins of two progestogens used during cyclic hormone replacement therapy
112. Short-term changes in lipoproteins and apoproteins during cyclical oestrogen-progestogen replacement therapy
113. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with cyclical estrogen/progestogen regimen
114. The effect of long-term oestrogen replacement therapy on glucose and lipid metabolism in postmenopausal women
115. The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women
116. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women
117. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women
118. Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women
119. Short-term effects of Org OD 14 and 17 beta-oestradiol on bone and lipid metabolism in early post-menopausal women
120. Early effects of continuous low-dosage all-norgestrel administered alone or with estrogen
121. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women
122. Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with estradiol
123. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17-beta-estradiol on lipid and lipoprotein profiles
124. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women
125. Prolonged effects of a novel, low-dosage continuous progestin-cyclic estrogen replacement program in postmenopausal women
126. Desogestrel in hormone replacement therapy; long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
127. Treatment-induced cyclic variations in serum lipids, lipoproteins, and apolipoproteins after 2 years of combined hormone replacement therapy; exaggerated cyclic variations in smokers
128. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins
129. Lipoproteins during oral and cutaneous administration of oestradiol-17 beta to menopausal women
130. High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women
131. Differential lipaemic and hormonal responses to oral and parenteral 17 beta-estradiol in postmenopausal women
132. Biological effects of estradiol-17 beta in postmenopausal women; oral versus percutaneous administration
133. Comparative metabolic study of percutaneous versus oral micronized 17 beta-oestradiol in replacement therapy
134. Differential effects of oral estrone versus 17 beta-estradiol on lipoproteins in postmenopausal women
135. Hepatic lipase activity during oral and parenteral 17 beta-estradiol replacement therapy; high-density lipoprotein increase may not be antiatherogenic
136. 17β-estradiol improves postprandial lipid metabolism in postmenopausal women
137. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions
138. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women
139. Fibrinogen and plasminogen modifications during oral oestradiol replacement therapy
140. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
141. Metabolism of apo(a) and apoB100 of lipoprotein (a) in women; effect of postmenopausal estrogen replacement
142. Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women
143. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy
144. Metabolic effects of continuous estradiol-progestin therapy on postmenopausal women
145. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women
146. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern
147. 17 Beta-estradiol and continuous norethisterone; a unique treatment for established osteoporosis in elderly women
148. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women; effect on plasma lipoproteins in a two-year placebo-controlled trial
149. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device
150. Different effects of continuous oestrogen-progestin and transdermal estrogen with cyclic progestin regimens on low-density lipoprotein subclasses
151. Hormone replacement therapy lowers plasma Lp(a) concentrations
152. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens
153. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women
154. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women
155. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis
156. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women; effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects
157. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate
158. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women; placebo-controlled trial of its gynecologic and metabolic actions
159. A continuous estrogen-progestogen regimen for climacteric complaints
160. Effect on lipoproteins of Trisequens, a combined hormone preparation
161. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy
162. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women
163. Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in post-menopausal women
164. Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment
165. Effect of 17 beta-oestradiol and norethisterone acetate on vertebral bone mass and lipid metabolism in early postmenopausal women
166. Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women
167. A randomised comparison of the effects of oral versus transdermal 17 beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels
168. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women; no additional unfavourable effects of dydrogesterone
169. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone; effect on calcium and lipid metabolism
170. Hormone replacement therapy with dydrogesterone progestin and estradiol-17β; effects on serum lipoproteins and on glucose tolerance during 24 month follow-up
171. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women
172. Long-term influence of different hormone replacement regimens on serum lipids and lipoprotein(a); a randomised study
173. Clinical equivalence of intranasal and oral 17 beta-estradiol for postmenopausal symptoms
174. Postmenopausal oestrogen replacement and lipids
175. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. A 2-year double-blind placebo study
176. Effects on lipids and lipoproteins in women treated with oestradiol and progesterone
177. Acute effects of estradiol and progesterone on insulin, lipids and lipoproteins in postmenopausal women; a pilot study
178. Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women
179. Effect of progestogens on estrogen-induced lipoprotein changes
180. Effects of oestradiol administration via different routes on the lipid profile in women with bilateral oophorectomy
181. Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch
182. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate
183. A randomised study to compare the efficacy and safety of a new 17-oestradiol transdermal matrix patch with estraderm TTS 50 in hysterectomised postmenopausal women
184. Effects of postmenopausal hormone replacement and alpha-tocopherol on the lipid profiles and antioxidant status
185. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins
186. Effects of long-term transdermal administration of estradiol on serum lipids
187. Differential effect of transdermal estrogen plus progestogen replacement therapy on insulin metabolism in postmenopausal women; relation to their insulinemic secretion
188. The effect of estradiol and a combined estradiol/progestogen preparation on insulin sensitivity in healthy postmenopausal women
189. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women; a randomized study
190. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
191. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate; the effects on lipoprotein metabolism in postmenopausal women
192. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women
193. Transdermal estrogen therapy in menopause. Eighteen months follow-up
194. Long-term treatment with transcutaneous estradiol and oral medroxyprogesterone acetate
195. Hormonal and metabolic effects of transdermal estradiol/progestogen administration in postmenopausal women
196. Alpha-tocopherol and beta-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetate
197. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause
198. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen; vasomotor symptoms, bleeding patterns, and serum lipids
199. Effects of transdermal oestrogen therapy in postmenopausal women; a comparative study of an oestradiol gel and an oestradiol delivering patch
200. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate
201. A transdermal regimen for continuous combined hormone replacement therapy in the menopause
202. A randomised comparison of nonoral estradiol delivery in postmenopausal women
203. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women
204. Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy
205. Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids
206. Metabolic changes induced by peroral oestrogen and transdermal oestradiol gel therapy
207. Lipid effects of an intrauterine device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol
208. Subdermal estradiol pellets following hysterectomy and oophorectomy
209. The effect of oestrogen implants on high density lipoproteins and its subfractions in women in their pre-mature menopause
210. Lipid and lipoprotein levels following pure estradiol implantation in post-menopausal women
211. Metabolic and hormonal effects of 25mg and 50mg 17 beta estradiol implants in surgically menopausal women
212. Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. II. Plasma lipids
213. The effect of oestradiol valerate therapy on coagulation factors and lipid and oestrogen levels in oophorectomised women
214. Lipid and carbohydrate metabolism studies in oophorectomized women; effects produced by the addition of norethisterone acetate to two estrogen preparations
215. High density lipoprotein-2 and hepatic lipase; reciprocal changes produced by estrogen and norgestrel
216. Estrogen induction of liver proteins and high-density lipoprotein cholesterol; comparison between estradiol valerate and ethinyl estradiol
217. Dose and duration effects of estradiol valerate on serum and lipoprotein lipids
218. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women
219. A comparison of the effects of ethinyl estradiol and estradiol valerate on serum and lipoprotein lipids
220. Hormone replacement therapy; lipid responses to continuous combined oestrogen and progestogen versus oestrogen monotherapy
221. Lipoprotein(a) and postmenopausal oestrogen
222. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause
223. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy; relation to lipoprotein(a) levels
224. HRT and exercise; effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women
225. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women
226. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss; long-term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding
227. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables
228. Serum lipids during oestradiol-valerate/norgestrel treatment of menopausal women. Double-blind study of a sequential preparation
229. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy
230. Subfractions of high density lipoprotein cholesterol during oestrogen replacement therapy; a comparison between progestogens and natural progesterone
231. Clinical experience with a low-dose combination of estradiol valerate and levonorgestrel. Double-blind comparative study between SH D 386 F and Cyclabil. Effects on symptoms, lipids and endometrial condition
232. Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel
233. Effects of oestradiol valerate plus two different progestogens on serum lipids during post-menopausal replacement therapy
234. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment
235. Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome
236. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause
237. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
238. Postmenopausal hormone replacement therapy and autoantibodies against LDL
239. Changes in lipoproteins and subfractions following oophorectomy and oestrogen replacement in peri-menopausal women
240. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
241. Effect of estrogen on fasting serum cholesterol and triglyceride levels in postmenopausal women
242. Effect of estrone sulfate on postmenopausal bone loss
243. Effects of estropipate treatment on plasma lipids and lipoprotein lipid composition in postmenopausal women
244. Biologic effects of 17 alpha-dihydroequilin sulfate
245. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein
246. Treatment with oral estrone sulphate in the female climacteric. I. Influence on lipids
247. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women
248. Benefits and risks of different hormonal replacement therapies in post-menopausal women
249. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women
250. Changes in lipidic and haemostatic parameters induced by tibolone treatment
251. Tibolone; influence on markers of cardiovascular disease
252. Effect of tibolone on glucose and lipid metabolism in postmenopausal women
253. Continuous combined hormone replcement therapy compared with tibolone
254. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
255. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group
256. The effect of treatment with oestradiol and oestriol on fasting serum cholesterol and triglyceride levels in postmenopausal women
257. Prospective double-blind study of CEE3 in peri- and postmenopausal women; effects on bone loss and lipoprotein lipids
258. Cardiovascular risk factors and combined estrogen-progestin replacement therapy; a placebo-controlled study with nomegestol acetate and estradiol
259. Effects of 4 mg estradiol valerianate on serum lipids in newly oophorectomized women
260. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations
261. Effects on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone
262. Lipoprotein(a) serum levels in post-menopausal women treated with oral estrogens administered at different times
263. Effect of postmenopausal hormone therapy on lipoprotein (a) concentration
264. Raloxifene lowers serum lipoprotein (a) in healthy postmenopausal women; a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens
265. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein (a)